The ROE as of September 2024 (TTM) for Trevi Therapeutics, Inc. (TRVI) is -49.92%

According to Trevi Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -49.92%. This represents a change of 285.48% compared to the average of -12.95% of the last 4 quarters.

Trevi Therapeutics, Inc. (TRVI) Historical ROE (quarterly & annually)

How has TRVI ROE performed in the past?

The mean historical ROE of Trevi Therapeutics, Inc. over the last ten years is -71.37%. The current -49.92% ROE has changed -30.05% with respect to the historical average. Over the past ten years (40 quarters), TRVI's ROE was at its highest in in the June 2018 quarter at 0%. The ROE was at its lowest in in the March 2022 quarter at -70.05%.

Trevi Therapeutics, Inc. (TRVI) ROE by Quarter and Year

Discovering the peaks and valleys of Trevi Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Trevi Therapeutics, Inc. (TRVI) Average ROE

How has TRVI ROE performed in the past?

The current ROE of Trevi Therapeutics, Inc. (TRVI) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Trevi Therapeutics, Inc. (TRVI) ROE vs. Peers

How is TRVI’s ROE compared to its peers?

Trevi Therapeutics, Inc.’s ROE is greater than aTyr Pharma, Inc. (-56.83%), greater than Cue Biopharma, Inc. (-142.93%), greater than AN2 Therapeutics, Inc. (-54.72%), greater than BioAtla, Inc. (-169.69%), less than Spero Therapeutics, Inc. (20.70%), greater than Bolt Biotherapeutics, Inc. (-61.40%), less than Coherus BioSciences, Inc. (23.81%), greater than Gracell Biotechnologies Inc. (-37.20%), greater than Neoleukin Therapeutics, Inc. (-47.64%), less than Foghorn Therapeutics Inc. (140.34%), greater than C4 Therapeutics, Inc. (-44.60%), greater than Cyteir Therapeutics, Inc. (-23.13%), greater than Prelude Therapeutics Incorporated (-59.82%), greater than Rezolute, Inc. (-60.90%), greater than Lyra Therapeutics, Inc. (-143.74%), greater than SQZ Biotechnologies Company (-10.98%), greater than Protara Therapeutics, Inc. (-55.03%), greater than TRACON Pharmaceuticals, Inc. (-237.65%), greater than Seer, Inc. (-21.26%), greater than ORIC Pharmaceuticals, Inc. (-40.19%), greater than Anebulo Pharmaceuticals, Inc. (-122.97%), greater than Cullinan Oncology, Inc. (-28.37%),

Build a custom stock screener for Trevi Therapeutics, Inc. (TRVI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Trevi Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Trevi Therapeutics, Inc. (TRVI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Trevi Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.